Rapport Therapeutics is a biopharmaceutical company using its receptor associated proteins technology platform focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Co.'s lead therapeutic candidate, RAP-219, is an AMPA receptor designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. The RAPP average annual return since 2024 is shown above.
The Average Annual Return on the RAPP average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RAPP average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RAPP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|